NCT06054854 Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)
| NCT ID | NCT06054854 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Lung Nodule |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2024-06-13 |
| Primary Completion | 2033-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2024-06-13 with a primary completion date of 2033-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The BIRD biobank aims at collecting clinical and biological data from patients suffering from a chronic respiratory disease. The lung cancer subpopulation will be divided into two cohorts to identify biomarkers of cancer. One cohort will include patients with supra-centimetric lung nodule(s) whether surveillance, bronchoscopic or radio-guided biopsy or surgery is indicated, patients suspected of lung cancers requiring diagnostic and/or therapeutic bronchial endoscopy and patients with a known early stage lung cancer (early-stage cohort). The second cohort will include known advanced stage lung cancers (III-IV).
Eligibility Criteria
Inclusion Criteria: * Patients with 1 to 3 lung nodules including one \> 1 cm seen on chest CT * OR: patients with suspected lung cancer requiring diagnostic and/or therapeutic bronchial endoscopy * OR: Patient with histologically confirmed lung cancer, whether early stages prior to surgery, locally advanced or metastatic, included before the start of any anti-cancer treatment. * Patient affiliated or beneficiary of a social security scheme * Patients who are able to receive and understand information about the study and their participation and who have freely given their signed inform consent before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and knowledge of the French language). Exclusion Criteria: * Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice * Female patients who are pregnant or breastfeeding
Contact & Investigator
Nicolas GUIBERT
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT06054854 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Nodule. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06054854 currently recruiting?
Yes, NCT06054854 is actively recruiting participants. Contact the research team at guibert.n@chu-toulouse.fr for enrollment information.
Where is the NCT06054854 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT06054854 clinical trial?
NCT06054854 is sponsored by University Hospital, Toulouse. The principal investigator is Nicolas GUIBERT at University Hospital, Toulouse. The trial plans to enroll 3,000 participants.